Nanomedicines for Overcoming Cancer Drug Resistance

Area of Science:

• Oncology
• Nanotechnology
• Drug Delivery Systems

Background:

• Cancer drug resistance to chemotherapy, targeted therapy, and immunotherapy is a primary obstacle to curative treatment.
• This resistance leads to treatment failure, increased healthcare costs, and higher mortality rates.
• Nanotechnology-based delivery systems are gaining attention to address these challenges in cancer therapy.

Purpose of the Study:

• To review mechanisms of cancer drug resistance.
• To discuss the latest advancements in nanomedicines for overcoming cancer drug resistance.
• To highlight the potential of nanotechnology in improving cancer treatment precision and monitoring.

Main Methods:

• Review of existing literature on cancer drug resistance mechanisms.
• Analysis of recent developments in nanotechnology-based drug delivery systems.
• Discussion of various nanomedicine platforms, including liposomes, polymer micelles, nanoparticles (NPs), and DNA nanostructures.

Main Results:

• Nanomedicines demonstrate potential in overcoming multidrug resistance (MDR) and other forms of cancer drug resistance.
• Tumor-targeting nanomedicines enable more precise cancer treatment and convenient monitoring.
• Various nanotechnology-based delivery systems are being developed for enhanced therapeutic efficacy.

Conclusions:

• Nanotechnology-based delivery systems represent a significant strategy for overcoming cancer drug resistance.
• Novel nanomedicines offer effective therapeutic approaches to surmount limitations of conventional cancer therapies.
• Continued research in nanomedicine is crucial for advancing cancer treatment and improving patient outcomes.